Synergy Pharmaceuticals introduces the small step for natural medicine, one giant leap for ending herpes
16 août 2021 07h59 HE
|
Synergy Pharmaceuticals
Melbourne, Australia, Aug. 16, 2021 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals is proud to introduce its product against herpes, as nearly 800,000 people are newly infected with herpes each year....
Recent Discovery in the Cure for Herpes is Overshadowed by the Covid -19 Quest for a Vaccine
07 juil. 2020 12h09 HE
|
Synergy Pharmaceuticals
Sydney, Australia, July 07, 2020 (GLOBE NEWSWIRE) -- The race is on to find a vaccine for COVID-19, the illness caused by the novel coronavirus. With an estimated 9 million cases and almost half a...
Synergy Pharmaceuticals Announces Change in Presentation Time at Jefferies 2013 Global Healthcare Conference
03 juin 2013 10h16 HE
|
Synergy Pharmaceuticals
NEW YORK, June 3, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced a change in the...
Synergy Pharmaceuticals to Present at Jefferies 2013 Global Healthcare Conference
31 mai 2013 06h00 HE
|
Synergy Pharmaceuticals
NEW YORK, May 31, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal diseases and disorders, today announced that its President...
Synergy Pharmaceuticals Added to the MSCI Global Small Cap Indices
30 mai 2013 06h00 HE
|
Synergy Pharmaceuticals
NEW YORK, May 30, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has been...
Synergy Pharmaceuticals Appoints Patrick H. Griffin, M.D. as Chief Medical Officer
29 mai 2013 16h31 HE
|
Synergy Pharmaceuticals
NEW YORK, May 29, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, announced today the appointment of...
Synergy Pharmaceuticals Presents Plecanatide Results From a Large Multicenter Clinical Study at Late-Breaking Abstract Session During Digestive Disease Week 2013
21 mai 2013 10h00 HE
|
Synergy Pharmaceuticals
NEW YORK, May 21, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat patients with gastrointestinal disorders and diseases, today presented positive...
Synergy Pharmaceuticals Added to NASDAQ Biotechnology Index
14 mai 2013 08h29 HE
|
Synergy Pharmaceuticals
NEW YORK, May 14, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today announced that it has been...
Synergy Pharmaceuticals Reports First Quarter 2013 Financial Results
09 mai 2013 17h26 HE
|
Synergy Pharmaceuticals
NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal disorders and diseases, today reported its financial results...
Synergy Pharmaceuticals' Chief Scientific Officer to Give Plenary Lecture on Plecanatide and SP-333 at the 15th Annual TIDES Summit
09 mai 2013 08h01 HE
|
Synergy Pharmaceuticals
NEW YORK, May 9, 2013 (GLOBE NEWSWIRE) -- Synergy Pharmaceuticals Inc. (Nasdaq:SGYP), a developer of new drugs to treat patients with gastrointestinal disorders and diseases, today announced its Chief...